In COVID-19 clinical update #72, Daniel Griffin covers long term symptoms in children, outcomes for MIS-C, recent guidance from the American Academy of Pediatrics, a large well traced outbreak of delta variant, low dose mRNA vaccination generates durable T cell memory and antibodies, protective immunity in recovered patients, assessment of BinaxNOW, no effect of oral azithromycin, post-discharge symptoms in Nigeria, and therapeutics for low and middle income countries.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

Long COVID in children (JAMA)
Outcomes after MIS-C (Pediatrics)
Guidance for school opening (Amer Acad Ped)
Infection in well traced delta outbreak (medRxiv)
Immune memory 8 months post-infection (Science)
Low dose mRNA vaccine enhances T cells (medRxiv)
Protection after infection (Lancet)
Assessment of BinaxNOW (Sci Rep)
Rapid POC antigen tests (Cochrane Rev)
Oral azithromycin ineffective (JAMA)
Post discharge symptoms in Nigeria (AJTMH)
Therapeutics for low and middle income countries (AJTMH)
Letters read on TWiV 783
Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

TWiV 783: COVID-19 clinical update #72 with Dr. Daniel Griffin